Intranasal administration of opioids/fentanyl - Physiological and pharmacological aspects

European Journal of Pain Supplements

Volumn 4, Issue 3, 2010, Pages 187-190

  Dale, Ola ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; INSTANYL; METHADONE; MORPHINE; OXYMETAZOLINE; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER PAIN; CANCER PATIENT; CAPILLARY PERMEABILITY; CEREBROSPINAL FLUID; COMMON COLD; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; DRUG UPTAKE; HUMAN; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MUCOCILIARY CLEARANCE; NOSE CAVITY; NOSE IRRITATION; NOSE MUCOSA; OLFACTORY EPITHELIUM; PHARYNX; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RHINITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77956886479     PISSN: 17543207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eujps.2010.06.001     Document Type: Article

References (32)

1. Andersen I., Proctor D.F. Measurement of nasal mucociliary clearance. Eur J Respir Dis Suppl 1983, 127:37-40.
2. Bailey F., Farley A. Oral opioid drugs. Cancer-related breakthrough pain 2006, 43-56. Oxford University Press, Oxford. A. Davies (Ed.).
3. Bennett D., Burton A.W., Fishman S., Fortner B., McCarberg B., Miaskowski C., et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2, management. P T 2005, 30:354-361.
4. Christrup L.L., Foster D., Popper L.D., Troen T., Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008, 30:469-481.
5. Coda B.A., Rudy A.C., Archer S.M., Wermeling D.P. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg 2003, 97:117-123.
6. Constantino H.R., Illum L., Brandt G., Johnson P.H., Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007, 337:1-24.
7. Dale O., Hjortkjær R., Kharasch E.D. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002, 46:759-770.
8. Dale O., Hoffer C., Sheffels P., Kharasch E.D. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther 2002, 72:536-545.
9. Davies A.N., Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage 2005, 30:496-497.
10. Farrar J.T., Portenoy R.K., Berlin J.A., Kinman J.L., Strom B.L. Defining the clinically important difference in pain outcome measures. Pain 2000, 88:287-294.
11. Fitzgibbon D., Morgan D., Dockter D., Barry C., Kharasch E.D. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 2003, 106:309-315.
12. Foster D., Upton R., Christrup L., Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 2008, 42:1380-1387.
13. Gervasi P.G., Longo V., Naldi F., Panattoni G., Ursino F. Xenobiotic-metabolizing enzymes in human respiratory nasal mucosa. Biochem Pharmacol 1991, 41:177-184.
14. Hanks G.W., de Conno F., Cherny N., Hanna M., Kalso E., McQuay H.J., et al. Expert working group of the research network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001, 84:587-593.
15. Illum L. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol 2004, 56:3-17.
16. Kaasa S., Moksnes K., Nolte T., Lefebvre-Kuntz D., Popper L., Kress H.-G. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manage 2010, 6:17-26.
17. Kress H.G., Orońska A., Kaczmarek Z., Kaasa S., Colberg T., Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009, 31:1177-1191.
18. Mercadante S., Radbruch L., Davies A., Poulain P., Sitte T., Perkins P., et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009, 25:2805-2815.
19. Moksnes K., Fredheim O.M., Klepstad P., Kaasa S., Angelsen A., Nilsen T., et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?. Eur J Clin Pharmacol 2008, 64:497-502.
20. Mygind N. Nasal allergy 1978, Blackwell Scientific Publications, Oxford, p. 3-38.
21. Nave R, Sides EH, Colberg T, Lophaven S, Meng X, Lahu G, et al. Higher systemic bioavailability and faster absorption of intranasal spray (INFS) compared to Actiq® (OTFC) in healthy subjects. Poster presented at the 6th Congress of the European Federation of IASP® Chapters (EFIC), Lisbon, Portugal, September 9th-12th, 2009a.
22. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Poster presented at the 6th Congress of the European Federation of IASP® Chapters (EFIC), Lisbon, Portugal, September 9th-12th, 2009b.
23. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Poster presented at the 6th Congress of the European Federation of IASP® Chapters (EFIC), Lisbon, Portugal, September 9th-12th, 2009c.
24. Pontiroli A.E., Calderara A., Pozza G. Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin Pharmacokinet 1989, 17:299-307.
25. Popper L, Nolte T, Kaczmarek Z, Orońska A, Kaasa S, Sopata M. Intranasal fentanyl for relief of breakthrough pain in patients with cancer. Poster presented at the 12th World Congress on Pain (WCP), Glasgow, Scotland, August 17th-22nd, 2008.
26. Sakane T., Yamashita S., Nadai T., Sezaki H. Direct drug transport from the nasal cavity to the cerebrospinal fluid. A new strategy for drug delivery to the brain. STP Pharma Sci 1997, 7:98-106.
27. Sarkar M.A. Drug metabolism in the nasal mucosa. Pharm Res 1992, 9:1-9.
28. Shyu W.C., Pittman K.A., Robinson D.S., Barbhaiya R.H. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. Eur J Clin Pharmacol 1993, 45:559-562.
29. Sigurdsson P., Thorvaldsson T., Gizurarson S., Gunnarsson E. Olfactory absorption of insulin to the brain. Drug Deliv 1997, 4:195-200.
30. Thornton-Manning J.R., Nikula K.J., Hotchkiss J.A., Avila K.J., Rohrbacher K.D., Ding X., et al. Nasal cytochrome P450 2A: identification, regional localization, and metabolic activity toward hexamethylphosphoramide, a known nasal carcinogen. Toxicol Appl Pharmacol 1997, 142:22-30.
31. Tortora G.J., Grabowski S.R. The respiratory system. Principles of anatomy and physiology, 9th ed 2000, 777. John Wiley & Sons, Inc., USA. G.J. Tortora, S.R. Grabowski (Eds.).
32. World Health Organization. Use of analgesics. In: World Health Organization. Cancer pain relief. With a guide to opioid availability. 2nd ed. Geneva: World Health Organization Geneva 1996. p. 14-6.